Methods in molecular biology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 14
Published: Jan. 1, 2025
Language: Английский
Frontiers in Cellular and Infection Microbiology, Journal Year: 2025, Volume and Issue: 14
Published: Jan. 20, 2025
Messenger RNA (mRNA) vaccines offer an adaptable and scalable platform for cancer immunotherapy, requiring optimal design to elicit a robust targeted immune response. Recent advancements in bioinformatics artificial intelligence (AI) have significantly enhanced the design, prediction, optimization of mRNA vaccines. This paper reviews technologies that streamline vaccine development, from genomic sequencing lipid nanoparticle (LNP) formulation. We discuss how accurate predictions neoantigen structures guide sequences effectively target cells. Furthermore, we examine AI-driven approaches optimize mRNA-LNP formulations, enhancing delivery stability. These technological innovations not only improve but also enhance pharmacokinetics pharmacodynamics, offering promising avenues personalized immunotherapy.
Language: Английский
Citations
10
Journal of Chromatography A, Journal Year: 2025, Volume and Issue: unknown, P. 465724 - 465724
Published: Jan. 1, 2025
Language: Английский
Citations
3
Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13
Published: March 12, 2025
The advent of mRNA vaccines, accelerated by the global response to COVID-19 pandemic, marks a transformative shift in vaccine technology. In this article, we discuss development, current applications, and prospects vaccines for both prevention treatment infectious diseases oncology. By leveraging capacity encode antigens within host cells directly, provide versatile scalable platform suitable addressing broad spectrum pathogens tumor-specific antigens. We highlight recent advancements design, innovative delivery mechanisms, ongoing clinical trials, with particular emphasis on their efficacy combating diseases, such as COVID-19, Zika, influenza, well emerging potential cancer immunotherapy. also address critical challenges, including stability, optimization immune responses, broader issue accessibility. Finally, review strategies advancing next-generation aim overcoming limitations technology enhancing preventive therapeutic approaches oncological diseases.
Language: Английский
Citations
3
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Nov. 14, 2024
Abstract In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great interest in both immunotherapy and non-immunogenic applications. This surge can be largely attributed to demonstration of distinct advantages offered by various mRNA molecules, alongside rapid advancements nucleic delivery systems. It is noteworthy that immunogenicity presents a double-edged sword. context immunotherapy, extra supplementation adjuvant generally required for induction robust immune responses. Conversely, non-immunotherapeutic scenarios, activation unwanted considering host tolerability high expression demand mRNA-encoded functional proteins. Herein, mainly focused on linear non-replicating mRNA, we overview preclinical clinical progress prospects medicines encompassing vaccines other therapeutics. We also highlight importance focusing host-specific variations, including age, gender, pathological condition, concurrent medication individual patient, maximized efficacy safety upon administration. Furthermore, deliberate potential challenges may encounter realm disease treatment, current endeavors improvement, as well application future advancements. Overall, this review aims present comprehensive understanding mRNA-based therapies while illuminating prospective development drugs.
Language: Английский
Citations
17
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Nov. 29, 2024
Language: Английский
Citations
17
Biomedicines, Journal Year: 2024, Volume and Issue: 12(9), P. 2158 - 2158
Published: Sept. 23, 2024
Cancer immunotherapy has emerged as a transformative approach in oncology, utilizing the body’s immune system to specifically target and destroy malignant cells. This review explores scope impact of various immunotherapeutic strategies, including monoclonal antibodies, chimeric antigen receptor (CAR)-T cell therapy, checkpoint inhibitors, cytokine therapeutic vaccines. Monoclonal such Rituximab Trastuzumab, have revolutionized treatment paradigms for lymphoma breast cancer by offering targeted interventions that reduce off-target effects. CAR-T therapy presents potentially curative option refractory hematologic malignancies, although challenges remain effectively treating solid tumors. Checkpoint inhibitors redefined management cancers like melanoma lung cancer; however, managing immune-related adverse events ensuring durable responses are critical areas focus. Cytokine continues play vital role modulating response, with advancements engineering improving specificity reducing systemic toxicity. Therapeutic vaccines, particularly mRNA-based represent frontier personalized treatment, aiming generate robust, long-lasting against tumor-specific antigens. Despite these advancements, field faces significant challenges, resistance, tumor heterogeneity, immunosuppressive microenvironment. Future research should address obstacles through emerging technologies, next-generation Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-based gene editing, AI-driven drug discovery. By integrating novel approaches, holds promise more durable, less toxic, highly options, ultimately patient outcomes survival rates.
Language: Английский
Citations
13
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 12284 - 12284
Published: Nov. 15, 2024
RNA therapeutics have undergone remarkable evolution since their inception in the late 1970s, revolutionizing medicine by offering new possibilities for treating previously intractable diseases. The field encompasses various modalities, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), and messenger (mRNAs), each with unique mechanisms applications. foundation was laid 1978 discovery that synthetic could inhibit viral replication, followed pivotal developments such as interference's 1998. COVID-19 pandemic marked a crucial turning point, demonstrating potential of mRNA vaccines accelerating interest RNA-based approaches. However, significant challenges remain, stability issues, delivery to target tissues, off-target effects, immunogenicity concerns. Recent advancements chemical modifications, systems, integration AI technologies are addressing these challenges. has seen notable successes, approved treatments spinal muscular atrophy hereditary transthyretin-mediated amyloidosis. Looking ahead, show promise personalized approaches, particularly genetic disorders cancer. continued this field, driven technological innovations deeper understanding biology, suggests transformative impact on future medical treatments. purpose review is provide comprehensive overview evolution, current state, prospects therapeutics.
Language: Английский
Citations
11
Molecular Biomedicine, Journal Year: 2025, Volume and Issue: 6(1)
Published: Jan. 10, 2025
Abstract Cancer vaccines, crucial in the immunotherapeutic landscape, are bifurcated into preventive and therapeutic types, both integral to combating oncogenesis. Preventive cancer like those against HPV HBV, reduce incidence of virus-associated cancers, while vaccines aim activate dendritic cells cytotoxic T lymphocytes for durable anti-tumor immunity. Recent advancements vaccine platforms, such as synthetic peptides, mRNA, DNA, cellular, nano-vaccines, have enhanced antigen presentation immune activation. Despite US Food Drug Administration approval several full potential remains unrealized due challenges selection, tumor-mediated immunosuppression, optimization delivery systems. This review provides a comprehensive analysis aims implications vaccine, innovative discovery neoantigens enhancing specificity, latest strides platforms. It also critically evaluates role adjuvants immunogenicity mitigating immunosuppressive tumor microenvironment. The further examines synergistic combining with other therapies, chemotherapy, radiotherapy, checkpoint inhibitors, improve outcomes. Overcoming barriers effective identification, microenvironments, adverse effects is critical advancing development. By addressing these challenges, can offer significant improvements patient outcomes broaden scope personalized immunotherapy.
Language: Английский
Citations
2
Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 184, P. 117897 - 117897
Published: Feb. 7, 2025
Language: Английский
Citations
2
Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: Jan. 6, 2025
Immuno-oncology has witnessed remarkable advancements in the past decade, revolutionizing landscape of cancer therapeutics an encouraging manner. Among diverse immunotherapy strategies, mRNA vaccines have ushered a new era for therapeutic management malignant diseases, primarily due to their impressive impact on COVID-19 pandemic. In this comprehensive review, we offer systematic overview vaccines, focusing optimization structural design, crucial role delivery materials, and administration route. Additionally, summarize preclinical studies clinical trials provide valuable insights into current status treatment. Furthermore, delve discussion significant challenges facing development tumor vaccines. These encompass both intrinsic external factors that are closely intertwined with successful application innovative approach. To pave way more promising future treatments, deeper understanding immunological mechanisms, increasing number high-quality trials, well-established manufacturing platform crucial. Collaborative efforts between scientists, clinicians, industry engineers essential achieving these goals.
Language: Английский
Citations
1